News & insights

Cambridge, UK – 30 April 2024: Cambridge Cognition, a leading provider of digital health solutions for brain health assessment, has announced that The Michael J. Fox Foundation for Parkinson’s Disease Research will incorporate its CANTAB® cognitive assessments into the Parkinson’s Progression Markers Initiative (PPMI).  The landmark initiative will use Cambridge Cognition’s...

by Martina De LilloClinical ScientistCambridge Cognition Disorders of the Central Nervous System (CNS) affect billions of people worldwide (The Lancet Neurology, 2022), representing an important cause of death and disability around the world. Life expectancy has been extended in the last years which has increased the number of brain pathologies...

Cambridge, UK – 23 April 2024: Cambridge Cognition Holdings plc (AIM: COG), which develops and markets digital solutions to assess brain health, is pleased to announce that Monument Therapeutics Limited (“Monument”) a precision neuroscience company spun-out from, and partly owned by Cambridge Cognition, has completed a £1.0 million fundraise and announced...

We caught up with the 2023 CANTAB Research Grant Secondary Award Winner, Louise Engelbrecht, who tells us how the grant will help to provide a better understanding of cognitive function during ultra-endurance performance and the role of ketone ester supplements to retain cognitive function. ​ I was elated when I...

Cambridge, UK – 10 April 2024: Cambridge Cognition, a leader in digital health solutions for brain health assessment, has announced the appointments of Alex Livingstone-Learmonth as Chief Commercial Officer and Annabelle Miles as Head of Marketing. These strategic additions mark a significant step as the Company continues strengthening its senior...